Search

Your search keyword '"Vlad, Catalin"' showing total 6 results
Start Over Author "Vlad, Catalin" Publisher bmj publishing group ltd
6 results on '"Vlad, Catalin"'

1. #746 Molecular analysis of BRCA and hrd status from small biopsies in high grade serous carcinoma. a real-world comparative analysis

Author

Kubelac, Paul, primary, Avram, Anca, additional, Turcas, Adrian, additional, Roman, Andrei, additional, Piciu, Andra, additional, Pasca, Andrei, additional, Gata, Vlad, additional, Tripac, Irina, additional, Pop, Bogdan, additional, Balacescu, Ovidiu, additional, Vlad, Catalin, additional, and Achimas-Cadariu, Patriciu, additional

Published
2023
Full Text
View/download PDF

3. #239 Analysis of the molecular profile of endometrial cancer depending on microsatelite instability

Author

Irina, Tripac, primary, Valentina, Stratan, additional, Valeriu, Tutuianu, additional, Victor, Sitnic, additional, Cristina, Popa, additional, Jean, Calleja-Agius, additional, Mariela, Vasileva-Slaveva, additional, Vlad, Catalin, additional, Harasani, Klejda, additional, Vladimir, Bucinskii, additional, Japaridze, Nino, additional, and Aliona, Dobrovolskaia, additional

Published
2023
Full Text
View/download PDF

6. Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?

Author

Constantinescu C, Pasca S, Tat T, Teodorescu P, Vlad C, Iluta S, Dima D, Tomescu D, Scarlatescu E, Tanase A, Sigurjonsson OE, Colita A, Einsele H, and Tomuleasa C

Subjects
Humans, Cell- and Tissue-Based Therapy methods, Continuous Renal Replacement Therapy methods, Cytokine Release Syndrome therapy, Immunotherapy methods
Abstract

Recently, an increasing number of novel drugs were approved in oncology and hematology. Nevertheless, pharmacology progress comes with a variety of side effects, of which cytokine release syndrome (CRS) is a potential complication of some immunotherapies that can lead to multiorgan failure if not diagnosed and treated accordingly. CRS generally occurs with therapies that lead to highly activated T cells, like chimeric antigen receptor T cells or in the case of bispecific T-cell engaging antibodies. This, in turn, leads to a proinflammatory state with subsequent organ damage. To better manage CRS there is a need for specific therapies or to repurpose strategies that are already known to be useful in similar situations. Current management strategies for CRS are represented by anticytokine directed therapies and corticosteroids. Based on its pathophysiology and the resemblance of CRS to sepsis and septic shock, as well as based on the principles of initiation of continuous renal replacement therapy (CRRT) in sepsis, we propose the rationale of using CRRT therapy as an adjunct treatment in CRS where all the other approaches have failed in controlling the clinically significant manifestations., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results